HBsAg / Hepatitis B Surface Antigen

HBsAg stands for Hepatitis B Surface Antigen. It is one of the blood tests used in hepatitis B screening and assessment. A single result may need to be interpreted with other hepatitis B markers, history and clinical context.

HBsAg detects hepatitis B surface antigen in blood. A reactive result can indicate current hepatitis B infection, but interpretation should not rely on HBsAg alone. CDC recommends using a hepatitis B serologic panel that also considers total anti-HBc and anti-HBs because the combination helps distinguish acute infection, chronic infection, past infection, vaccination and susceptibility.

A recently vaccinated person can occasionally have transient HBsAg positivity, and reactive screening results may require confirmation according to the assay and laboratory process. Clinical follow-up may include additional hepatitis B markers and HBV DNA depending on the situation.

Hepatitis B testing is strongest when the appropriate markers are ordered together. CDC commonly describes a three-test screening panel using HBsAg, total anti-HBc and anti-HBs because the combination can distinguish susceptibility, vaccination-related immunity, previous infection and current infection more effectively than HBsAg alone. If HBsAg is reactive, follow-up depends on the full serology pattern, symptoms, liver tests and sometimes HBV DNA. People concerned about a recent exposure should discuss timing because testing too early can miss an infection that has not yet produced detectable markers.

HBsAg is used when screening for or evaluating current hepatitis B infection. Additional hepatitis B markers may be needed to determine infection stage, immunity or previous exposure.

HBsAg is a qualitative hepatitis B marker. A nonreactive result means surface antigen was not detected by that assay at the time of testing. A reactive result can indicate current hepatitis B infection, but it should be interpreted with other hepatitis B markers—commonly total anti-HBc and anti-HBs—and with clinical history. This combination helps distinguish current infection, past infection, susceptibility and vaccine-related immunity.

If recent exposure is a concern, timing matters because markers may not be detectable immediately. Recent hepatitis B vaccination can also cause transient HBsAg reactivity in some circumstances.

HBsAg alone cannot determine whether hepatitis B is acute or chronic, whether a person is immune, or how active infection may be. A negative result does not exclude very early infection. Reactive screening results and discordant patterns may require confirmatory or additional testing according to the reporting laboratory and clinician.

A blood sample is used and fasting is not required. If hepatitis B status is being assessed rather than only HBsAg requested, ask whether a complete hepatitis B panel is more appropriate so the result can be interpreted properly.